The Biden administration’s proposed framework for exercising "march-in rights" under the Bayh-Dole Act represents a radical policy shift that prioritizes price controls and consumer access over traditional innovation incentives. By introducing pricing and availability as potential criteria for compulsory licensing of federally funded inventions, the administration departs significantly from historical interpretations of the law. Critics argue this approach lacks legal grounding and threatens to undermine the foundational balance between rewarding inventors and serving the public interest. Transparency concerns are central to the backlash, as stakeholders accuse the administration of developing this framework behind closed doors without meaningful public engagement. The Government Accountability Project’s Chamber of Commerce Global Innovation Policy Center has filed FOIA requests to uncover communications between the interagency working group and advocates for price controls, seeking to understand if external political pressures influenced the draft guidance. This lack of visibility into the decision-making process has fueled fears that the policy was crafted without adequate scrutiny or stakeholder input, violating norms of open governance. This issue is critical to the open data and open innovation communities because it threatens the economic viability of startups and small inventors who rely on federal funding and intellectual property protections. If corporations anticipate reduced returns on R&D due to potential price-based licensing, they may shift investments away from high-risk, early-stage innovations, ultimately stifling medical and technological breakthroughs. The resulting chilling effect on small innovators could distort the open market, making it harder for independent researchers and small businesses to participate in the broader ecosystem of publicly funded discovery.
Source:Published on 2024-01-11